Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) announced on Wednesday that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its chikungunya vaccine candidate.
Bavarian Nordic's single-dose vaccine is designed to prevent chikungunya infection in people aged 12 and older.
The application benefits from accelerated assessment granted by the EMA in February 2024, potentially leading to European Commission approval in the first half of 2025.
The chikungunya vaccine demonstrated strong immune response in two Phase 3 trials with over 3,600 participants and was well-tolerated with mostly mild or moderate side effects.
myTomorrows names new director
GSK's Arexvy receives positive CHMP opinion for at-risk adults aged 50-59
Latigo Biotherapeutics names new chief executive officer
Valneva receives CEPI funding to boost access to world's first chikungunya vaccine
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
GSK secures global rights to CureVac's mRNA vaccines in new licensing deal
INOVIO names new chief commercial officer
Dynavax Technologies commences dosing in Z-1018 phase 1/2 clinical trial
Bavarian Nordic files for chikungunya vaccine approval in Europe
Valneva's chikungunya vaccine IXCHIQ approved by Health Canada
Philippine lawmakers call for probe into secret US propaganda operation
Gavi seeking funding to immunise poorest children
Sanofi partners with Biovac to manufacture polio vaccines in Africa